Gene · 8505
Papers1,648
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,648
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells. | Oncogene | 2025 | 40234721 | PubTator, text mining | PubMed |
| Family-wide analysis of human macrodomains reveals novel activities and identifies PARG as most efficient ADPr-RNA hydrolase. | Commun Biol | 2025 | 40102620 | PubTator, text mining | PubMed |
| Targeting dePARylation in cancer therapy. | DNA Repair (Amst) | 2025 | 40056493 | PubTator, text mining | PubMed |
| Discovery of reversing enzymes for RNA ADP-ribosylation reveals a possible defence module against toxic attack. | Nucleic Acids Res | 2025 | 39964479 | PubTator, text mining | PubMed |
| [Banxia Xiexin Decoction suppresses malignant phenotypes of colon cancer cells via PARG/PARP1/NF-κB signaling pathway]. | Zhongguo Zhong Yao Za Zhi | 2025 | 39929630 | PubTator, text mining | PubMed |
| Increasing cellular NAD+ protects hepatocytes against palmitate-induced lipotoxicity by preventing PARP-1 inhibition and the mTORC1-p300 pathway activation. | Am J Physiol Cell Physiol | 2025 | 39871470 | PubTator, text mining | PubMed |
| RECQL4 requires PARP1 for recruitment to DNA damage, and PARG dePARylation facilitates its associated role in end joining. | Exp Mol Med | 2025 | 39870799 | PubTator, text mining | PubMed |
| Integrated Genomics Reveal Potential Resistance Mechanisms of PANoptosis-Associated Genes in Acute Myeloid Leukemia. | Mol Carcinog | 2025 | 39868611 | PubTator, text mining | PubMed |
| Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. | Chem Rev | 2025 | 39818743 | PubTator, text mining | PubMed |
| Poly(ADP-ribose) polymerase FonPARP1-catalyzed PARylation of protein disulfide isomerase FonPdi1 regulates pathogenicity of Fusarium oxysporum f. sp. niveum on watermelon. | Int J Biol Macromol | 2025 | 39708869 | PubTator, text mining | PubMed |
| Prospects for PARG inhibitors in cancer therapy. | J Mol Cell Biol | 2025 | 39668635 | PubTator, text mining | PubMed |
| Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents. | Neoplasia | 2025 | 39615107 | PubTator, text mining | PubMed |
| Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39557132 | PubTator, text mining | PubMed |
| Effect of Culture Supernatant of Clostridium butyricum TO-A on Human DNA-Repair-Factor-Encoding Gene Promoters. | Int J Mol Sci | 2024 | 39596217 | PubTator, text mining | PubMed |
| PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer. | Proc Natl Acad Sci U S A | 2024 | 39546575 | PubTator, text mining | PubMed |
| PARP enzyme de novo synthesis of protein-free poly(ADP-ribose). | Mol Cell | 2024 | 39536748 | PubTator, text mining | PubMed |
| PARG inhibition induces nuclear aggregation of PARylated PARP1. | Structure | 2024 | 39406247 | PubTator, text mining | PubMed |
| ADP-ribose hydrolases: biological functions and potential therapeutic targets. | Expert Rev Mol Med | 2024 | 39375922 | PubTator, text mining | PubMed |
| Reversal of tyrosine-linked ADP-ribosylation by ARH3 and PARG. | J Biol Chem | 2024 | 39342999 | PubTator, text mining | PubMed |
| Divalent and multivalent cations control liquid-like assembly of poly(ADP-ribosyl)ated PARP1 into multimolecular associates in vitro. | Commun Biol | 2024 | 39278937 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8505/papers?page=4